Steve Bryson, PhD, science writer —

Dry-powder corticosteroid inhalers, or those designed to have a low impact on climate, are as effective as those based on pressurized, metered doses at reducing the risk of poor outcomes in people with both chronic obstructive pulmonary disease (COPD) and asthma. A large study in Denmark found the two…

Exposure to certain air pollution gases — pollutants called volatile organic compounds (VOCs), especially benzene and toluene — significantly increases the risk of chronic obstructive pulmonary disease (COPD) among adults in the U.S., according to a new study. Indeed, one statistical model found COPD risk was three times higher…

Dupixent (dupilumab) as an add-on maintenance treatment significantly eased exacerbations and lung symptom severity while improving lung function and quality of life — among people with moderate to severe chronic obstructive pulmonary disease (COPD). That’s according to published data from the Phase 3 NOTUS clinical trial (NCT04456673), which…

Travel times limit access to pulmonary rehabilitation programs to help people with chronic lung conditions, such as chronic obstructive pulmonary disease (COPD), a U.S. report revealed. Data showed about 80% of people live within a 30-minute drive of a rehabilitation site, mostly those who reside within major urban and…

Yupelri (revefenacin) is not superior to Spiriva (tiotropium) at improving lung function in adults with severe chronic obstructive pulmonary disease (COPD), according to data from a Phase 4 clinical trial. The head-to-head study, called PIFR-2 (NCT05165485) and sponsored by Yupelri’s co-developers Theravance Biopharma and…

Marpai, an artificial intelligence-powered administrator of employer health plans, is partnering with NuvoAir to provide virtual care for heart and lung conditions such as chronic obstructive pulmonary disease (COPD) to its health plan members and their families. “We are thrilled to offer NuvoAir to address the high-cost…

Nighttime breathing symptoms related to chronic obstructive pulmonary disease (COPD) significantly impaired daily activities and health-related quality of life, a survey of patients and physicians revealed. Most of the surveyed patients (74%) reported having nocturnal symptoms, while physicians reported that they prescribed treatments based on 24-hour symptom relief for…

Nuance Pharma has been given the go-ahead to launch clinical trials in China to evaluate the investigational therapy ensifentrine as a maintenance treatment for chronic obstructive pulmonary disease (COPD). The company asked permission, in the form of an investigational new drug (IND) application, to conduct both Phase 1…

Salmeterol, combined with the root extract derivative magnesium isoglycyrrhizinate (MgIG), eased the signs and symptoms of chronic obstructive pulmonary disease (COPD) in rats, a study demonstrated. Salmeterol-MgIG combination therapy was more effective than the approved salmeterol-fluticasone combination in improving lung function and reducing inflammation. The researchers suggested…

Scientists say the discovery of a triggering enzyme in the lung tissue of people with severe chronic obstructive pulmonary disease (COPD) could lead to a new treatment for the inflammatory disorder. Elevated levels of the newly uncovered enzyme, called chymase-1 or CMA-1, were found in tissue isolated from the lungs…